Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample.

La Joie R, Bejanin A, Fagan AM, Ayakta N, Baker SL, Bourakova V, Boxer AL, Cha J, Karydas A, Jerome G, Maass A, Mensing A, Miller ZA, O'Neil JP, Pham J, Rosen HJ, Tsai R, Visani AV, Miller BL, Jagust WJ, Rabinovici GD.

Neurology. 2018 Jan 23;90(4):e282-e290. doi: 10.1212/WNL.0000000000004860. Epub 2017 Dec 27.

PMID:
29282337
2.

Frontal presentation of Alzheimer's disease: a series of patients with biological evidence by CSF biomarkers.

de Souza LC, Bertoux M, Funkiewiez A, Samri D, Azuar C, Habert MO, Kas A, Lamari F, Sarazin M, Dubois B.

Dement Neuropsychol. 2013 Jan-Mar;7(1):66-74. doi: 10.1590/S1980-57642013DN70100011.

3.

Analysis of a case series of behavioral variant frontotemporal dementia: emphasis on diagnostic delay.

Guimarães HC, Vale TC, Pimentel V, de Sá NC, Beato RG, Caramelli P.

Dement Neuropsychol. 2013 Jan-Mar;7(1):55-59. doi: 10.1590/S1980-57642013DN70100009.

4.

PET/MR Imaging: New Frontier in Alzheimer's Disease and Other Dementias.

Zhang XY, Yang ZL, Lu GM, Yang GF, Zhang LJ.

Front Mol Neurosci. 2017 Nov 1;10:343. doi: 10.3389/fnmol.2017.00343. eCollection 2017. Review.

5.

The emerging role of PET imaging in dementia.

Iaccarino L, Sala A, Caminiti SP, Perani D.

F1000Res. 2017 Oct 12;6:1830. doi: 10.12688/f1000research.11603.1. eCollection 2017. Review.

6.

Urine AD7c-NTP Predicts Amyloid Deposition and Symptom of Agitation in Patients with Alzheimer's Disease and Mild Cognitive Impairment.

Zhang N, Zhang L, Li Y, Gordon ML, Cai L, Wang Y, Xing M, Cheng Y.

J Alzheimers Dis. 2017;60(1):87-95. doi: 10.3233/JAD-170383.

7.

A clinicopathological approach to the diagnosis of dementia.

Elahi FM, Miller BL.

Nat Rev Neurol. 2017 Aug;13(8):457-476. doi: 10.1038/nrneurol.2017.96. Epub 2017 Jul 14. Review.

8.

Frontotemporal Dementia.

Olney NT, Spina S, Miller BL.

Neurol Clin. 2017 May;35(2):339-374. doi: 10.1016/j.ncl.2017.01.008. Review.

PMID:
28410663
9.
10.

Typical and atypical pathology in primary progressive aphasia variants.

Spinelli EG, Mandelli ML, Miller ZA, Santos-Santos MA, Wilson SM, Agosta F, Grinberg LT, Huang EJ, Trojanowski JQ, Meyer M, Henry ML, Comi G, Rabinovici G, Rosen HJ, Filippi M, Miller BL, Seeley WW, Gorno-Tempini ML.

Ann Neurol. 2017 Mar;81(3):430-443. doi: 10.1002/ana.24885. Epub 2017 Mar 20.

PMID:
28133816
11.

Memory loss: Five new things.

Deak F, Kapoor N, Prodan C, Hershey LA.

Neurol Clin Pract. 2016 Dec;6(6):523-529. doi: 10.1212/CPJ.0000000000000314.

12.

Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort.

Seo SW, Ayakta N, Grinberg LT, Villeneuve S, Lehmann M, Reed B, DeCarli C, Miller BL, Rosen HJ, Boxer AL, O'Neil JP, Jin LW, Seeley WW, Jagust WJ, Rabinovici GD.

Neuroimage Clin. 2016 Nov 11;13:130-137. eCollection 2017.

13.

The Eye As a Biomarker for Alzheimer's Disease.

Lim JK, Li QX, He Z, Vingrys AJ, Wong VH, Currier N, Mullen J, Bui BV, Nguyen CT.

Front Neurosci. 2016 Nov 17;10:536. eCollection 2016. Review.

14.

Diagnostic utility of ASL-MRI and FDG-PET in the behavioral variant of FTD and AD.

Tosun D, Schuff N, Rabinovici GD, Ayakta N, Miller BL, Jagust W, Kramer J, Weiner MM, Rosen HJ.

Ann Clin Transl Neurol. 2016 Aug 30;3(10):740-751. eCollection 2016 Oct.

15.

Applied multimodal diagnostics in a case of presenile dementia.

Schönecker S, Brendel M, Huber M, Vollmar C, Huppertz HJ, Teipel S, Okamura N, Levin J, Rominger A, Danek A.

BMC Neurol. 2016 Aug 9;16:131. doi: 10.1186/s12883-016-0647-7.

16.

Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study.

Leuzy A, Chiotis K, Hasselbalch SG, Rinne JO, de Mendonça A, Otto M, Lleó A, Castelo-Branco M, Santana I, Johansson J, Anderl-Straub S, von Arnim CA, Beer A, Blesa R, Fortea J, Herukka SK, Portelius E, Pannee J, Zetterberg H, Blennow K, Nordberg A.

Brain. 2016 Sep;139(Pt 9):2540-53. doi: 10.1093/brain/aww160. Epub 2016 Jul 7.

17.

Blood protein predictors of brain amyloid for enrichment in clinical trials?

Ashton NJ, Kiddle SJ, Graf J, Ward M, Baird AL, Hye A, Westwood S, Wong KV, Dobson RJ, Rabinovici GD, Miller BL, Rosen HJ, Torres A, Zhang Z, Thurfjell L, Covin A, Hehir CT, Baker D, Bazenet C, Lovestone S; AIBL Research Group.

Alzheimers Dement (Amst). 2015 Mar 29;1(1):48-60. doi: 10.1016/j.dadm.2014.11.005. eCollection 2015 Mar.

18.

Amyloid imaging for dementia in Canada.

Laforce R Jr, Bensaïdane MR.

CMAJ. 2016 May 17;188(8):598-602. doi: 10.1503/cmaj.150663. Epub 2016 Apr 11. No abstract available.

19.

Frontotemporal Dementias.

Finger EC.

Continuum (Minneap Minn). 2016 Apr;22(2 Dementia):464-89. doi: 10.1212/CON.0000000000000300. Review.

20.

Insight into the Molecular Imaging of Alzheimer's Disease.

Arora A, Bhagat N.

Int J Biomed Imaging. 2016;2016:7462014. doi: 10.1155/2016/7462014. Epub 2016 Jan 10. Review.

Supplemental Content

Support Center